HIV vaccine development has been hampered by the inability of conventional
immunogens to elicit antibodies capable of neutralizing primary isolates of
the virus. Recent studies using 'fusion-competent' immunogens that capture
transitional intermediate structures of the functioning envelope protein s
uggest that this goal may now be achievable. (C) 2000 Editions scientifique
s et medicales Elsevier SAS.